Literature DB >> 14749354

Synergistic induction of the nicotinamide adenine dinucleotide-linked 15-hydroxyprostaglandin dehydrogenase by an androgen and interleukin-6 or forskolin in human prostate cancer cells.

Min Tong1, Hsin-Hsiung Tai.   

Abstract

The nicotinamide adenine dinucleotide-dependent 15-hydroxyprostaglandin dehydrogenase (15-PGDH) catalyzes the oxidation of 15 (S)-hydroxyl group of prostaglandins and lipoxins and participates along with cyclooxygenases and lipoxygenases in controlling the cellular levels of prostaglandins and lipoxins. 15-PGDH could be induced by IL-6 and forskolin in addition to androgens in a time- and dose-dependent manner but not by other cytokines and growth factors in LNCaP cells. Concurrent addition of IL-6 and forskolin showed additive effect in the induction of 15-PGDH activity. However, combined addition of dihydrotestosterone (DHT) and IL-6 or DHT plus forskolin exhibited synergistic induction of 15-PGDH activity. The increase in enzyme activity was correlated with the expression of the enzyme protein as shown by Western blot analysis. The induction by DHT or IL-6 or forskolin or their combinations was inhibited by antiandrogen, casodex, in a dose-dependent manner, indicating that a functional androgen receptor was required for the action of any of these three agents. The induction by forskolin plus DHT or by either agent or by IL-6 alone was greatly inhibited by H-89, indicating the involvement of protein kinase A in the actions of forskolin, DHT, and IL-6. The induction of 15-PGDH by IL-6 was also blocked by some other protein kinase inhibitors, indicating the participation of MAPK, MAPK/ERK kinase, and STAT3 in the signaling pathway of IL-6. These results indicate that the induction of 15-PGDH by DHT, IL-6, and forskolin in LNCaP cells may involve a functional androgen receptor and phosphorylation-dependent multiple signaling pathways.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14749354     DOI: 10.1210/en.2003-1229

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  10 in total

Review 1.  Prostaglandins and cancer.

Authors:  D Wang; R N Dubois
Journal:  Gut       Date:  2005-08-23       Impact factor: 23.059

2.  Inverse expression of prostaglandin E2-related enzymes highlights differences between diverticulitis and inflammatory bowel disease.

Authors:  Liying Dai; Denis W King; D Shevy Perera; David Z Lubowski; Elizabeth Burcher; Lu Liu
Journal:  Dig Dis Sci       Date:  2015-02-11       Impact factor: 3.199

3.  TISSUE REGENERATION. Inhibition of the prostaglandin-degrading enzyme 15-PGDH potentiates tissue regeneration.

Authors:  Yongyou Zhang; Amar Desai; Sung Yeun Yang; Ki Beom Bae; Monika I Antczak; Stephen P Fink; Shruti Tiwari; Joseph E Willis; Noelle S Williams; Dawn M Dawson; David Wald; Wei-Dong Chen; Zhenghe Wang; Lakshmi Kasturi; Gretchen A Larusch; Lucy He; Fabio Cominelli; Luca Di Martino; Zora Djuric; Ginger L Milne; Mark Chance; Juan Sanabria; Chris Dealwis; Debra Mikkola; Jacinth Naidoo; Shuguang Wei; Hsin-Hsiung Tai; Stanton L Gerson; Joseph M Ready; Bruce Posner; James K V Willson; Sanford D Markowitz
Journal:  Science       Date:  2015-06-12       Impact factor: 47.728

4.  15-PGDH is reduced and induces apoptosis and cell cycle arrest in gastric carcinoma.

Authors:  Li-Hong Lou; Da-Dao Jing; Yue-Xing Lai; Ying-Ying Lu; Ji-Kun Li; Kai Wu
Journal:  World J Gastroenterol       Date:  2012-03-14       Impact factor: 5.742

Review 5.  Targeting inflammation: multiple innovative ways to reduce prostaglandin E₂.

Authors:  Jessica K Norberg; Earlphia Sells; Hui-Hua Chang; Srinivas R Alla; Shuxing Zhang; Emmanuelle J Meuillet
Journal:  Pharm Pat Anal       Date:  2013-03

6.  15-Hydroxyprostaglandin dehydrogenase is down-regulated in colorectal cancer.

Authors:  Michael G Backlund; Jason R Mann; Vijaykumar R Holla; F Gregory Buchanan; Hsin-Hsiung Tai; Erik S Musiek; Ginger L Milne; Sharada Katkuri; Raymond N DuBois
Journal:  J Biol Chem       Date:  2004-11-12       Impact factor: 5.157

7.  Limited effect of anti-rheumatic treatment on 15-prostaglandin dehydrogenase in rheumatoid arthritis synovial tissue.

Authors:  Karina Roxana Gheorghe; Syed Sadique; Patrick Leclerc; Helena Idborg; Ivonne Wobst; Anca Irinel Catrina; Per-Johan Jakobsson; Marina Korotkova
Journal:  Arthritis Res Ther       Date:  2012-05-22       Impact factor: 5.156

8.  15-PGDH inhibition activates the splenic niche to promote hematopoietic regeneration.

Authors:  Julianne Np Smith; Dawn M Dawson; Kelsey F Christo; Alvin P Jogasuria; Mark J Cameron; Monika I Antczak; Joseph M Ready; Stanton L Gerson; Sanford D Markowitz; Amar B Desai
Journal:  JCI Insight       Date:  2021-03-22

9.  miR-485-5p binding site SNP rs8752 in HPGD gene is associated with breast cancer risk.

Authors:  Na He; Hong Zheng; Pei Li; Yanrui Zhao; Wei Zhang; Fengju Song; Kexin Chen
Journal:  PLoS One       Date:  2014-07-08       Impact factor: 3.240

10.  Relationship between 15-hydroxyprostaglandin dehydrogenase and gastric adenocarcinoma.

Authors:  Jae Hyun Kang; Sang Hyun Kang; Sang Hyuk Seo; Jae Ho Shin; Min Sung An; Tae Kwun Ha; Ki Beom Bae; Tae Hyun Kim; Chang Soo Choi; Sang Hoon Oh; Mi Seon Kang; Kwang Hee Kim
Journal:  Ann Surg Treat Res       Date:  2014-05-23       Impact factor: 1.859

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.